| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Malignant pleural mesothelioma (MPM) is mainly caused by exposure to asbestos, develops in the pleural cavity with a high likelihood of malignancy. Development of novel therapies for MPM is warranted in order to improve very poor prognosis. In this study, we investigated whether anti-human podoplanin antibodies can induce antitumor effects in MPM. Using podoplanin positive human MPM cell lines, anti-human podoplanin antibodies with NK cells induced significant antitumor effect. Our results strongly suggest that anti-human podoplanin antibodies might provide an efficacious therapeutic strategy for the treatment of MPM.
|
